SHREVEPORT, LA ― Lower back pain could soon be a thing of the past thanks to a new procedure that promises relief. The Louisiana Spine Institute in Shreveport hopes the Dascor Arthroplasty System will help millions of people who suffer from degenerative disc disease.
The surgery removes and replaces the nucleus of the disc in the lower spine to reduce pain without the need for total disc replacement.
Doctors are expecting a large number of people to participate in the clinical trial.
"So hopefully this will be a boost to the people suffering from disengenic back pain," Dr. Euby Kerr says.
Patients say they are excited about the breakthrough in back pain relief.
"It was just a breakthrough that way I wouldn't have to go through the disc fusions and stay out longer," spine surgery patient Katherine Hidalgo says.
The surgery is minimally invasive and requires less recovery time.
On the Web:
For more information, check http://www.louisianaspine.org/
Study found more germs and a wider variety of bacterial types in houses with dogs
But it's unclear what the finding might mean for patients
Hopelessness, disability may play a role in feelings of despair, study finds
But questions remain about widespread screening
Patients thought to have lung condition were re-evaluated in small study
NEW YORK (AP) — The nation's record-low teen birth rate stems from robust declines in nearly every state, but most dramatically in several Mountain States and among Hispanics, according to a new government report.
In a medical first, doctors used plastic particles and a 3-D laser printer to create an airway splint to save the life of a baby boy who used to stop breathing nearly every day.
WARSAW, Poland (AP) — A 33-year-old Polish man received a face transplant just three weeks after being disfigured in a workplace accident, in what his doctors said Wednesday is the fastest time frame to date for such an operation. It was Poland's first face transplant.
By Julie Steenhuysen CHICAGO (Reuters) - Kathrin Jansen is a microbiologist with at least two breakthrough vaccines to her name: she brought the cervical cancer vaccine Gardasil to market for Merck and helped develop the $4 billion a year pneumonia and meningitis vaccine Prevnar 13 for Pfizer. Jansen's next vaccine success could come by taming the superbug MRSA, a drug-resistant bacterium that she has seen ravage a healthy man up close and personally. Methicillin-resistant Staphylococcus aureus infects an estimated 53 million people globally and costs more than $20 billion a year to treat. ...
